Other groups have shown that glioma cases with gain of 7p, loss of 10q, and mutation in the TERT promoter biologically represent a different subtype, which is prognostically relevant and has clinical impact for proper risk stratification of patients and choice of treatment23–25. This evidence concerns the gene TERT and glioma.